All In Biotech

Drug Trial Radar · NCT07219849

A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure

A Two-part Adaptive Double-blind Randomized Placebo-controlled Study to Assess the Appropriate Dose and the Appropriate Dosing Frequency of ALDP 001 in Adults With Seasonal Allergic Rhinitis (SAR) Assessed Using an Allergen Challenge Chamber/EEC

Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Oct 17, 2025

Primary completion

Apr 2026

Study completion Apr 2026

Sponsor

Sponsor type
Industry
First posted
Oct 22, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the effectiveness and safety of ALDP001 Nasal Spray in treating seasonal allergic rhinitis, and to identify the optimal dosage and administration frequency for this formulation.

Conditions

  • Seasonal Allergic Rhinitis (SAR)

Interventions

  • ALDP001 Nasal SprayDrug

    Experimental Arm

  • Placebo Nasal sprayDrug

    Controlled arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Total Nasal Symptom ScoreTime frame: Day 9

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliantha Research

    Mississauga, Ontario, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.